Answer
Yes, Fem7 Conti is associated with an increased risk of breast cancer, with the risk dependent on the duration of HRT use.
Sources for this answer
- Fem7 Conti, 50 micrograms / 7 micrograms / 24 hours, Transdermal patchTheramex · emc · SmPC §4.4 Special warnings and precautions for use · Version 4Document updated
Sources checked